## PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mall Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 or Fax (57)-273-2885

INSTRUCTIONS: This appropriate. All further c indicated unless correcto maintenance fee notificati	form should he used it correspondence including d below or directed out	for trans ng the P nerwise	mitting the ISSU atent, advance or in Block I, by (a	E FEE and PUBLIC ders and notification ) specifying a new o						
CURRENT CORRESPONDENCE ADDRESS (Note: Use Block I for any change of address)						Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.				
26648	00 09/06/2007									
PHARMACIA CORPORATION GLOBAL PATENT DEPARTMENT POST OFFICE BOX 1027						I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2883, on the date indicated below.				
ST. LOUIS, MO 63006					Karol J Wilder (Ocpositors name)					
		Spine	third ( Nuder) (SI							
		6 December 2007 (Done)								
APPLICATION NO. FILING DATE			FIRST NAMED INVEN			TOR ATTORNEY DOCKET NO.			CONFIRMATION NO.	
10/727,168	arjotte Moira Norfor Allerton PC25420A 6748					6748				
TITLE OF INVENTION: MORPHOLINE DOPAMINE AGONISTS										
APPLN. TYPE	SMALL ENTITY	ISS	UE FEE DUÉ	PUBLICATION FEE	DUE	PREV. PAID ISSUE	E FEE	TOTAL FEE(S) DUE	DATE DUE	
nonprovisional	NO		\$1400	\$300		\$0		\$1700	12/06/2007	
EXAMINER			ART UNIT	CLASS-SUBCLAS	s					
SAEED, KAMAL A 1626				514-235200	514-235200					
Change of correspondence address or indication of "Fee Address" (37 CFR 1563).      Change of correspondence address (or Change of Correspondence Address form PTOSBI 122) attached.      Tee Address' indication (or "Fee Address" Indication form PTOSBI 47; Rev 03-02 or more recent) attached. Use of a Customer Number Is required.				2 For printing on the pasen front page, list (1) the names for the pasen front page, list (2) the name of a page that pasen attorneys or agents OR, alternatively. (2) the name of a single firm (baving as a member a registered attorney or agent) and the names of up to listed, to name will be printed.						
3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)										
PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patter. If an assignee is identified below, the document has been filed for recordation as set forch in 31 CFR 3.11. Completion of this form in 107 a substimite for filing an assignment.  (A) NAME OF ASSIGNEE  (B) RESIDENCE: (CITY and STATE OR COUNTRY)										
Pfizer Inc.	New York	New York, NY 10017-5755 USA								
Please check the appropriate assignee category or categories (will not be printed on the patent):										
4a. The following fee(s) a  22 Issue Fee  Publication Fee (N  Advance Order - #	b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)    A check is enclosed.     Payment by credit card. Form FTO-2038 is attached.     The Director is berely authorized to charge the graquityd fee(s), any deficiency, or credit any overpayment, to Deposit Account humber 16-14-14-2 (enclose an extra copy of this form).									
5. Change in Entity Status (from status indicated above)  a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27(g)(2).										
NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.										
Authorized Signature					cember 2007					
Typed or printed name			Registration N							
This collection of information is required by 37 CFR, 1311. The information is required to obtain or retain benefit by the public which is to fit (and by the LSPTO to precess) an application. Confidentially is givened by 35 LSPTO and 37 CFR, 1.41. This collection is estimated to late 17 minute to complete, for expension and confidentially is givened on spirit and the confidential by the completed application. Confidentially 1877 CA with the confidential properties of the confidential propert										

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.